Share Repurchases and Market Expansion Will Support Stronger Future Performance

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Feb 25

Updated

09 Dec 25

Views

39

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

69.3%

7D

-2.7%

Loading

1Y

69.3%

7D

-2.7%

You can edit this narrative until Dec 10 6:10 PM. Then, changes will post as Updates.

Author's Valuation

NOK 31519.4% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

MEDI: Stable Margins And Long Term Outlook Will Support Strong Future Performance

Analysts have modestly reaffirmed their outlook on Medistim, leaving the price target effectively unchanged at NOK 315, as they continue to point to stable long term growth assumptions and resilient profitability expectations. Valuation Changes Consensus Analyst Price Target remains unchanged at NOK 315, indicating no revision to the central valuation view.

Shared on 25 Nov 25

MEDI: Stable Outlook And Margins Will Support Confidence In Performance

Analysts have maintained their price target for Medistim at NOK 315.00. This indicates continued optimism about the company's stable outlook based on consistent key financial estimates and outlook assumptions.

Shared on 10 Nov 25

MEDI: Share Buyback Completion Will Drive Confidence In Future Performance

Narrative Update on Medistim Analysts have maintained their price target for Medistim at NOK 315.00, reflecting steady expectations and confidence in the company's underlying fundamentals. What's in the News Medistim completed the repurchase of 189,224 shares, representing 1.04% of outstanding shares, for NOK 12.5 million as part of its ongoing buyback program announced in March 2025 (Key Developments).

Shared on 27 Oct 25

Fair value Increased 8.62%

Analysts have raised their price target for Medistim from NOK 290 to NOK 315, citing improved revenue growth projections and higher expected profit margins. What's in the News Medistim completed the repurchase of 189,224 shares, representing 1.04% of its outstanding shares, for a total of NOK 12.5 million.

Shared on 09 Sep 25

Fair value Increased 14%

The significant upward revision in Medistim's price target is driven by higher consensus revenue growth forecasts and a rising future P/E multiple, resulting in the fair value increasing to NOK290.00. Valuation Changes Summary of Valuation Changes for Medistim The Consensus Analyst Price Target has significantly risen from NOK255.00 to NOK290.00.

Shared on 25 Aug 25

Fair value Increased 11%

Despite a reduction in consensus revenue growth forecasts and a higher future P/E, analysts have notably raised Medistim’s fair value estimate from NOK230.00 to NOK255.00. Valuation Changes Summary of Valuation Changes for Medistim The Consensus Analyst Price Target has significantly risen from NOK230.00 to NOK255.00.

Shared on 13 Mar 25

Fair value Increased 2.22%

AnalystConsensusTarget Fair Value

NOK 315

19.4% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

9.11%

Medical Equipment revenue growth rate

6.79%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.00%

Calculation

NOK 202.93m

Earnings '28

x

34.24x

PE Ratio '28

=

NOK 6.95b

Market Cap '28

NOK 6.95b

Market Cap '28

/

18.15m

No. shares '28

=

NOK 382.80

Share Price '28

NOK 382.80 Share Price '28

Discounted to 2025 @ 7.01% p.a.

=

NOK 312.39

Fair Value '25